Suspended treatment when serious chemotherapy toxicity, disease progression, or other diseases unsuitable for chemotherapy occurred. The chemotherapy regimens consisted of docetaxel + epirubicin + cyclophosphamide (TEC) and docetaxel + carboplatin + trastuzumab (TCbH) every 3 weeks before surgery. This study included 165 invasive breast cancer patients who receiving 2–6 cycles of NCT before surgery from July 2017 to May 2019. For those reasons, based on preoperative clinicopathological variables and simple laboratory indexes, we established a nomogram to calculate the probability of pCR in breast cancer patients who received NCT. There have been few well-designed nomograms predicting the probability of pCR in the literature, and the implications of providing a detailed probability of pCR in patients who receive NCT have not been well established. Nomograms in clinical settings are considered to be comprehensive predictive tools that can estimate the probabilities, risks or clinical outcomes. These factors should help us select the patients who will benefit most from treatment and recommend a tailored approach when choosing the initial treatment to give patients the best response to treatment and subsequent overall survival. Some baseline clinicopathological features can predict the curative effect of NCT for breast cancer and further reflect the long-term outcomes of patient treatment. However, only 5–38% of BC patients achieve pCR, meaning that the majority (those who cannot attain pCR) have a higher risk of death and recurrence. Several studies have found that BC patients who achieve pCR after NCT exhibit improved survival. “Patient level analysis” has shown that achieving pathologic complete response (pCR) under NCT is associated with an increase in event-free survival (EFS) and overall survival (OS). Neoadjuvant chemotherapy (NCT), which is increasingly offered to breast cancer patients, is mainly used to reduce tumor burden to enable breast-conserving surgery (BCS) and provide the opportunity to assess the response to treatment by an in vivo chemosensitivity test. There has been a gradual increase in the incidence of breast cancer. We developed a nomogram based on multiple clinical and biological covariations that can provide an early prediction of NCT response and can help to quickly assess the individual benefits of NCT.īreast cancer is the most common malignant tumor among women and the second leading cause of cancer-related death in America. The final prediction accuracy of cross-validation was 76%. ![]() According to the Hosmer-Lemeshow test, the calibration chart showed satisfactory agreement between the predicted and observed probabilities. The nomogram for pCR based on lymphovascular invasion, anemia (hemoglobin≤120 g/L), ER, Ki67 expression levels and NCT regimen had good discrimination performance (area under the curve, 0.758 95% confidence interval, 0.675–0.841) and calibration coordination. These predictors were used to develop a binary logistic regression model with cross-validation and to show the established predictive model with a nomogram. ![]() The correlation between biological markers and pCR was analyzed. Using pretreatment biopsy materials, immunohistochemical studies to assess estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), and Ki-67 expression. We selected 165 breast cancer patients receiving NCT from July 2017 to May 2019. This study intends to explore the clinical and biological factors in breast cancer patients receiving NCT and to establish a nomogram that can predict the pathologic complete response (pCR) rate of NCT. ![]() Combining multiple potential efficacy-related factors to build a model may improve the accuracy of prediction. Previous research results on the predictive factors of neoadjuvant chemotherapy (NCT) efficacy in breast cancer are inconsistent, suggesting that the ability of a single factor to predict efficacy is insufficient.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |